Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：14
|
作者：
Koerkamp, B. Groot [1 ]
Janssen, Q. P. [1 ]
van Dam, J. L. [1 ]
Bonsing, B. A. [2 ]
Bos, H. [3 ]
Bosscha, K. P. [4 ]
Haberkorn, B. C. M. [5 ]
de Hingh, I. H. J. T. [6 ]
Karsten, T. M. [7 ]
Van der Kolk, M. B. [8 ]
Liem, M. S. L. [9 ]
Loosveld, O. J. L. [10 ]
Patijn, G. A. [11 ]
van Santvoort, H. C. M. [12 ]
de Vos-Geelen, J. [13 ]
van der Holt, B. [14 ]
Homs, M. Y. V. [15 ]
van Tienhoven, G. [16 ]
Besselink, M. G. [17 ]
Wilmink, H. W. [18 ]
机构：
[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands
[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands
[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands
[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands
[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands
[6] Catharina Hosp, Surg, Eindhoven, Netherlands
[7] OLVG Hosp, Surg, Amsterdam, Netherlands
[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands
[9] Med Spectrum Twente, Surg, Enschede, Netherlands
[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands
[11] Isala Hosp, Surg, Zwolle, Netherlands
[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands
[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands
[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands
[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands
[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands
[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands
[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA83
引用
下载
收藏
页码：S1323 / S1323
页数：1
相关论文
共 50 条
  • [21] A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
    Palmer, Daniel H.
    Stocken, Deborah D.
    Hewitt, Helen
    Markham, Catherine E.
    Hassan, A. Bassim
    Johnson, Philip J.
    Buckels, John A. C.
    Bramhall, Simon R.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) : 2088 - 2096
  • [22] A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin
    Daniel H. Palmer
    Deborah D. Stocken
    Helen Hewitt
    Catherine E. Markham
    A. Bassim Hassan
    Philip J. Johnson
    John A. C. Buckels
    Simon R. Bramhall
    Annals of Surgical Oncology, 2007, 14 : 2088 - 2096
  • [23] Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial)
    van Dongen, Jelle C.
    Suker, Mustafa
    Versteijne, Eva
    Bonsing, Bert A.
    Mieog, J. Sven D.
    de Vos-Geelen, Judith
    van der Harst, Erwin
    Patijn, Gijs A.
    de Hingh, Ignace H.
    Festen, Sebastiaan
    Ten Tije, Albert J.
    Busch, Olivier R.
    Besselink, Marc G.
    van Tienhoven, Geertjan
    Koerkamp, Bas Groot
    van Eijck, Casper H. J.
    ANNALS OF SURGERY, 2022, 275 (05) : 979 - 984
  • [24] Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer : Meta-analysis and trial sequential analysis of randomized controlled trials
    Hajibandeh, Shahab
    Hajibandeh, Shahin
    Intrator, Christina
    Hassan, Karim
    Sehmbhi, Mantej
    Shah, Jigar
    Mazumdar, Eshan
    Kausar, Ambareen
    Satyadas, Thomas
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2023, 27 (01) : 28 - 39
  • [25] Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience
    Son, Chang O.
    Pai, Sachin Gopalkrishn
    Satti, Suma
    Dornelles, Adriana
    Bolton, John S.
    Conway, W. Charles
    Fuloria, Jyotsna
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [26] Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
    Neibart, Shane S.
    Mamidanna, Swati
    Chundury, Anupama
    Sayan, Mutlay
    Alexander, H. Richard
    August, David A.
    Berim, Lyudmyla D.
    Boland, Patrick M.
    Grandhi, Miral S.
    Gulhati, Prateek
    Hochster, Howard S.
    Langan, Russell C.
    Spencer, Kristen R.
    Kennedy, Timothy J.
    Deek, Matthew P.
    Jabbour, Salma K.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (06) : 2557 - +
  • [27] Clinical Outcomes of the Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine Versus FOLFIRINOX
    Choi, Y. J.
    Kang, J. S.
    Byun, Y.
    Kim, H. S.
    Han, Y.
    Kim, H.
    Kim, E.
    Kwon, W.
    Jang, J. Y.
    PANCREAS, 2019, 48 (10) : 1414 - 1414
  • [28] Efficacy of Neoadjuvant Chemotherapy Using Gemcitabine and S-1 for Resectable and Borderline Resectable Pancreatic Cancer
    Aoki, T.
    Mori, S.
    Sakuraoka, Y.
    Suzuki, T.
    Nishi, Y.
    Arakawa, T.
    Shimizu, T.
    Tago, K.
    Park, K. H.
    Harada, N.
    Shiraki, T.
    Iso, Y.
    Kubota, K.
    PANCREAS, 2019, 48 (10) : 1404 - 1404
  • [29] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Hozaeel, Wael
    Pauligk, Claudia
    Homann, Nils
    Luley, Kim
    Kraus, Thomas Werner
    Trojan, Jorg
    Bechstein, Wolf O.
    Grimm, Kersten
    Heise, Bettina
    Schmiegel, Wolff
    Pink, Daniel
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer—The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4121 - 4122
12345